

## PRESS RELEASE



### Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences

SUZHOU, China and PALO ALTO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming conferences:

#### **Goldman Sachs Asia Pacific Healthcare Forum 2021**

One-on-one and small group meetings (virtual): November 15-17, 2021

For more information, please contact your Goldman Sachs representative.

#### **8<sup>th</sup> BioCentury-BayHelix China Healthcare Summit**

In-person one-on-one and small group meetings (Shanghai, China): November 17, 2021

Panel - China Biotech CEO Blue Ribbon Roundtable: November 17, 2021, 14:30-15:15pm CST

For more information, please contact your Biocentury representative.

#### **Jefferies London Healthcare Conference**

One-on-one and small group meetings (virtual): November 18-19, 2021

Fireside Chat: available on-demand beginning on Thursday, November 18, 3:00am ET

Webcast link: <https://ir.gracellbio.com/news-events/events-and-presentations>

The replay of the fireside chat can be accessed through the "[News and Events](#)" section of the Gracell Investor website.

For more information, please contact your Jefferies representative.

#### **20<sup>th</sup> Morgan Stanley Annual Asia Pacific Summit**

One-on-one and small group meetings (virtual): November 18-19, 2021

For more information, please contact your Morgan Stanley representative.

#### **About Gracell**

Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit [www.gracellbio.com](http://www.gracellbio.com)

Follow @GracellBio on [LinkedIn](#)

#### **Media contact**

**Marvin Tang**

[marvin.tang@gracellbio.com](mailto:marvin.tang@gracellbio.com)

#### **Investor contact**

**Gracie Tong**

[gracie.tong@gracellbio.com](mailto:gracie.tong@gracellbio.com)

